Tural D, Selçukbiricik F, Ölmez ÖF, Sümbül AT, Erman M, Coşkun HŞ, Artaç M, Kılıçkap S
Int J Clin Oncol 2022 Mar;27(3):585-591. Epub 2021 Nov 11 doi: 10.1007/s10147-021-02072-x. PMID: 34762201

Atezolizumab in Patients with Metastatic Urothelial Carcinoma Who Have Progressed After First-line Chemotherapy: Results of Real-life Experiences.

Tural D, Ölmez ÖF, Sümbül AT, Artaç M, Özhan N, Akar E, Çakar B, Köstek O, Ekenel M, Erman M, Coşkun HŞ, Selçukbiricik F, Keskin Ö, Türköz FP, Oruç K, Bayram S, Yılmaz U, Bilgetekin İ, Yıldız B, Şendur MAN, Paksoy N, Dirican A, Erdem D, Selam M, Tanrıverdi Ö, Paydaş S, Urakçı Z, Atağ E, Güncan S, Ürün Y, Alkan A, Kaya AO, Özyükseler DT, Taşkaynatan H, Yıldırım M, Sönmez M, Başoğlu T, Gündüz Ş, Kılıçkap S
Eur Urol Focus 2021 Sep;7(5):1061-1066. Epub 2020 Sep 30 doi: 10.1016/j.euf.2020.09.010. PMID: 33008789

The pretreatment neutrophil-to-lymphocyte ratio is a novel biomarker for predicting clinical responses to pembrolizumab in platinum-resistant metastatic urothelial carcinoma patients.

Ogihara K, Kikuchi E, Shigeta K, Okabe T, Hattori S, Yamashita R, Yoshimine S, Shirotake S, Nakazawa R, Matsumoto K, Mizuno R, Hara S, Oyama M, Masuda T, Niwakawa M, Oya M
Urol Oncol 2020 Jun;38(6):602.e1-602.e10. Epub 2020 Mar 2 doi: 10.1016/j.urolonc.2020.02.005. PMID: 32139290

See all (3)

Diagnosis

The pretreatment neutrophil-to-lymphocyte ratio is a novel biomarker for predicting clinical responses to pembrolizumab in platinum-resistant metastatic urothelial carcinoma patients.

See all (1)

Therapy

Response to first-line chemotherapy regimen is associated with efficacy of ımmune checkpoint blockade therapies in patients with metastatic urothelial carcinoma.

Nivolumab in Patients with Advanced Platinum-resistant Urothelial Carcinoma: Efficacy, Safety, and Biomarker Analyses with Extended Follow-up from CheckMate 275.

Galsky MD, Saci A, Szabo PM, Han GC, Grossfeld G, Collette S, Siefker-Radtke A, Necchi A, Sharma P
Clin Cancer Res 2020 Oct 1;26(19):5120-5128. Epub 2020 Jun 12 doi: 10.1158/1078-0432.CCR-19-4162. PMID: 32532789 Free PMC Article

The pretreatment neutrophil-to-lymphocyte ratio is a novel biomarker for predicting clinical responses to pembrolizumab in platinum-resistant metastatic urothelial carcinoma patients.

Nivolumab in patients with unresectable locally advanced or metastatic urothelial carcinoma: CheckMate 275 2-year global and Japanese patient population analyses.

Ohyama C, Kojima T, Kondo T, Naya Y, Inoue T, Tomita Y, Eto M, Hisasue S, Uemura H, Obara W, Kikuchi E, Sharma P, Galsky MD, Siefker-Radtke A, Grossfeld G, Collette S, Gooden K, Kimura G
Int J Clin Oncol 2019 Sep;24(9):1089-1098. Epub 2019 Jun 19 doi: 10.1007/s10147-019-01450-w. PMID: 31218529

Sacituzumab Govitecan, a Novel Antibody--Drug Conjugate, in Patients With Metastatic Platinum-Resistant Urothelial Carcinoma.

Faltas B, Goldenberg DM, Ocean AJ, Govindan SV, Wilhelm F, Sharkey RM, Hajdenberg J, Hodes G, Nanus DM, Tagawa ST
Clin Genitourin Cancer 2016 Feb;14(1):e75-9. Epub 2015 Oct 19 doi: 10.1016/j.clgc.2015.10.002. PMID: 26541586

See all (5)